Revolutionary Non-Invasive Treatment Shows Promise
Recent clinical findings presented at the Korean Society of Brain Neuromodulation Therapy Winter Conference reveal groundbreaking advancements in treating normal pressure hydrocephalus (NPH) through ultrasound technology. Professor Kim Jae-ho from…
The government has announced £82.6 million in research funding to support UK companies tackling cancer and accelerating drug discovery using AI.
Three projects will benefit from this support, two of which will use AI to…
Baljean Dhillon, professor of clinical ophthalmology at the University of Edinburgh (Credit: andrewperry.co.uk)
Researchers are working with high street opticians to develop a digital tool that can predict a person’s risk of dementia from…
Continue Reading
What You Should Know:
– Lantheus Holdings, Inc. (NASDAQ: LNTH), a leading radiopharmaceutical company, announced a definitive agreement to acquire Life Molecular Imaging Ltd. for $350M upfront and up to an additional $400M in potential…
Continue Reading
Remote, digital cognitive testing on an individual’s own device provides the opportunity to deploy previously understudied but promising cognitive paradigms in preclinical Alzheimer’s disease (AD). The Boston Remote Assessment for NeuroCognitive Health (BRANCH) captures…
Continue Reading
What You Should Know:
– CareYaya Health Technologies, a leading innovator in AI-powered solutions for the aging population, has launched MedaCareLLM, a new AI platform designed to assist individuals with dementia and Alzheimer’s disease.
– Integrated…
Continue Reading
Alzheimer’s disease (AD) is a global healthcare challenge lacking a simple and affordable detection method. We propose a novel deep learning framework, Eye-AD, to detect Early-onset Alzheimer’s Disease (EOAD) and Mild Cognitive Impairment (MCI)…
Continue Reading
What You Should Know:
– GE HealthCare announced today that its MIM Software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a groundbreaking tool in the fight against Alzheimer’s disease.
–…
Continue Reading
The Remote Assessment of Disease and Relapse – Alzheimer’s Disease (RADAR-AD) consortium evaluated remote measurement technologies (RMTs) for assessing functional status in AD. The consortium engaged with the European Medicines Agency (EMA) to obtain…
Continue Reading
Dementia represents a significant global health challenge, with early screening during the preclinical stage being crucial for effective management. Traditional diagnostic biomarkers for Alzheimer’s Disease, the most common form of dementia, are limited by…
Continue Reading
